Daiichi Sankyo saw the highest growth of 1.13% in patent filings in April and 1.25% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.13% and grants by 1.18%. GlobalData’s DataBook provides a comprehensive analysis of Daiichi Sankyo‘s patent filings and grants. Buy the databook here.
Daiichi Sankyo has been focused on protecting inventions in Japan(JP) with 22 publications in Q2 2024
The Japan(JP) Patent Office dominates the patent filings and grants with nearly 17% filings and 22% grants. The Japan(JP), United States(US), China(CN), and Israel(IL) patent Office are among the top ten patent offices where Daiichi Sankyo is filings its patents. Among the top granted patent authorities, Daiichi Sankyo has 22% of its grants in Japan(JP), 19% in United States(US) and 16% in Israel(IL).
Roche could be the strongest competitor for Daiichi Sankyo
Patents related to rare diseases and climate change lead Daiichi Sankyo's portfolio
Daiichi Sankyo has the highest number of patents in rare diseases followed by, climate change and nanomedicine. For rare diseases, nearly 63% of patents were filed and 53% of patents were granted in Q2 2024.
Solid tumor related patents lead Daiichi Sankyo portfolio followed by manufacturing/industrial, and lymphoma
Daiichi Sankyo has highest number of patents in solid tumor followed by manufacturing/industrial, lymphoma, macular degeneration, and refining. For solid tumor, nearly 3% of patents were filed and 4% of patents were granted in Q2 2024.
For comprehensive analysis of Daiichi Sankyo's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.